KRAS and neoplasm: Thought to act as a downstream mediator of numerous oncogenic drivers, such as KRAS, EGFR, or mutated PTEN, PI3K-AKT-mTOR pathway signalling controls tumour development and regulates the cellular composition of the TME29,35,36.